Characteristics and risk factors of thyroid dysfunction induced after interferon therapy in patients with chronic viral hepatitis
10.3760/cma.j.issn.1673-4904.2014.16.014
- VernacularTitle:慢性病毒性肝炎干扰素治疗后致甲状腺功能异常的临床特征及危险因素分析
- Author:
Zhihe ZHANG
;
Xuefu CHEN
- Publication Type:Journal Article
- Keywords:
Hepatitis,viral,human;
Thyroid diseases;
Interferon-alpha;
Risk factors
- From:
Chinese Journal of Postgraduates of Medicine
2014;37(16):43-46
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the characteristics and risk factors of thyroid dysfunction induced after interferon therapy in patients with chronic viral hepatitis.Methods The clinical data of 96 chronic viral hepatitis patients received interferon therapy were analyzed retrospectively.Serological markers of thyroid function and thyroid autoantibodies changes were observed,and were followed up for 1 year after treatment.Logistic regression analysis was performed to evaluate risk factors of thyroid dysfunction.Results Among the 96 cases,84 cases didn't develop thyroid dysfunction after interferon therapy(normal group),and 12 cases developed thyroid dysfunction after interferon therapy (abnormal group),the incidence was 12.5％ (12/96),there were 5 cases of Hashimoto's thyroiditis,3 cases of Graves disease,3 cases of destructive thyroiditis,and 1 case of non-autoimmune hypothyroidism.The time to develop thyroid dysfunction was 2-7 (3.8 ± 1.9) months after treatment,the duration of thyroid dysfunction was 1-11 (4.2 ± 0.9) months.Five patients received endocrine therapy,and 2 patients stopped interferon therapy.All patients regained normal thyroid function during 1-year followup after end of treatment.Multivariate Logistic regression analysis showed that female gender (OR =3.767) and anti-thyroid peroxidase antibodies (OR =1.117) were the independent risk factors for thyoid dysfunction.Conclusions Hashimoto's thyroiditis,Graves disease,destructive thyroiditis and non-autoimmune hypothyroidism are the main types of thyroid dysfunction induced after interferon therapy in patients with chronic viral hepatitis.The thyroid function and thyroid autoantibodies should be closely monitored during treatment in patients with chronic viral hepatitis receiving interferon therapy,especially in female and patients who have thyroid autoantibodies.
